In conclusion, TFP5 treatment protects the kidney from hyperglycemia-induced damage by CDK5-NGF-Sirt1 regulation axis, and NGF and Sirt1 may be the novel target for DN. This evidence concerns the gene SIRT1 and liver dysplastic nodule.